BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.310
+0.030 (2.34%)
At close: Jan 22, 2026, 4:00 PM EST
1.360
+0.050 (3.82%)
Pre-market: Jan 23, 2026, 8:01 AM EST
BioCardia Revenue
In the year 2024, BioCardia had annual revenue of $58.00K, down -87.84%.
Revenue (ttm)
$58.00K
Revenue Growth
-87.84%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
13.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
| Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
| Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
| Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
| Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
| Dec 31, 2019 | 710.00K | 85.00K | 13.60% |
| Dec 31, 2018 | 625.00K | 146.00K | 30.48% |
| Dec 31, 2017 | 479.00K | -97.00K | -16.84% |
| Dec 31, 2016 | 576.00K | -328.00K | -36.28% |
| Dec 31, 2015 | 904.00K | 477.00K | 111.71% |
| Dec 31, 2014 | 427.00K | 159.00K | 59.33% |
| Dec 31, 2013 | 268.00K | 206.00K | 332.26% |
| Dec 31, 2012 | 62.00K | 50.00K | 416.67% |
| Dec 31, 2011 | 12.00K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | 1.27M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBCDA News
- 5 weeks ago - BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA - GlobeNewsWire
- 7 weeks ago - BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress - GlobeNewsWire
- 2 months ago - BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 - GlobeNewsWire
- 4 months ago - BioCardia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 4 months ago - BioCardia Announces Pricing of Up To $12 Million Public Offering - GlobeNewsWire